New clues to the molecular pathogenesis of myelodysplastic syndromes

Experimental Cell Research

Volumn 316, Issue 8, 2010, Pages 1390-1396

  Jädersten, Martin ^a   Hellström Lindberg, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CBL; Del(5q); Iron; MPL; RARS T; Ring sideroblast; SPARC

Indexed keywords

CBL PROTEIN; JANUS KINASE 2; MICRORNA; PROTEIN P53; PROTEIN RPS14; PROTEIN TET2; RIBOSOME PROTEIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

5Q- SYNDROME; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HAPLOTYPE; HUMAN; IRON METABOLISM; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SIDEROBLASTIC ANEMIA; THROMBOCYTOSIS; ANIMAL; GENETICS; MOLECULAR BIOLOGY;

ANIMALS; HUMANS; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROMES;

EID: 77952579886     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.02.043     Document Type: Review

References (46)

1. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., Schoch R., Gattermann N., Sanz G., List A., Gore S.D., Seymour J.F., Bennett J.M., Byrd J., Backstrom J., Zimmerman L., McKenzie D., Beach C., Silverman L.R. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009, 10:223-232.
2. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC Press, Lyon.
3. Van den Berghe H., Cassiman J.J., David G., Fryns J.P., Michaux J.L., Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974, 251:437-438.
4. Giagounidis A.A., Germing U., Haase S., Hildebrandt B., Schlegelberger B., Schoch C., Wilkens L., Heinsch M., Willems H., Aivado M., Aul C. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004, 18:113-119.
5. Boultwood J., Fidler C., Strickson A.J., Watkins F., Gama S., Kearney L., Tosi S., Kasprzyk A., Cheng J.F., Jaju R.J., Wainscoat J.S. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002, 99:4638-4641.
6. Nilsson L., Astrand-Grundstrom I., Arvidsson I., Jacobsson B., Hellstrom-Lindberg E., Hast R., Jacobsen S.E. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000, 96:2012-2021.
7. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., Raza A., Root D.E., Attar E., Ellis S.R., Golub T.R. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
8. Draptchinskaia N., Gustavsson P., Andersson B., Pettersson M., Willig T.N., Dianzani I., Ball S., Tchernia G., Klar J., Matsson H., Tentler D., Mohandas N., Carlsson B., Dahl N. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat. Gen. 1999, 21:169-175.
9. Amsterdam A., Sadler K.C., Lai K., Farrington S., Bronson R.T., Lees J.A., Hopkins N. Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol. 2004, 2:E139.
10. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., Sung S., Morin R., Muranyi A., Hirst M., Hogge D., Marra M., Wells R.A., Buckstein R., Lam W., Humphries R.K., Karsan A. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 2010, 16:49-58.
11. Barlow J.L., Drynan L.F., Hewett D.R., Holmes L.R., Lorenzo-Abalde S., Lane A.L., Jolin H.E., Pannell R., Middleton A.J., Wong S.H., Warren A.J., Wainscoat J.S., Boultwood J., McKenzie A.N. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat. Med. 2010, 16:59-66.
12. Pellagatti A., Jadersten M., Forsblom A.M., Cattan H., Christensson B., Emanuelsson E.K., Merup M., Nilsson L., Samuelsson J., Sander B., Wainscoat J.S., Boultwood J., Hellstrom-Lindberg E. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11406-11411.
13. Framson P.E., Sage E.H. SPARC and tumor growth: where the seed meets the soil?. J. Cell Biochem. 2004, 92:679-690.
14. Jadersten M., Saft L., Pellagatti A., Gohring G., Wainscoat J.S., Boultwood J., Porwit A., Schlegelberger B., Hellstrom-Lindberg E. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009, 94:1762-1766.
15. Ebert B.L. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009, 23:1252-1256.
16. Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin. Hematol. 2009, 46:371-377.
17. Guernsey D.L., Jiang H., Campagna D.R., Evans S.C., Ferguson M., Kellogg M.D., Lachance M., Matsuoka M., Nightingale M., Rideout A., Saint-Amant L., Schmidt P.J., Orr A., Bottomley S.S., Fleming M.D., Ludman M., Dyack S., Fernandez C.V., Samuels M.E. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat. Genet. 2009, 41:651-653.
18. Shimada Y., Okuno S., Kawai A., Shinomiya H., Saito A., Suzuki M., Omori Y., Nishino N., Kanemoto N., Fujiwara T., Horie M., Takahashi E. Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia. J. Hum. Genet. 1998, 43:115-122.
19. Pondarre C., Campagna D.R., Antiochos B., Sikorski L., Mulhern H., Fleming M.D. Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 2007, 109:3567-3569.
20. Cavadini P., Biasiotto G., Poli M., Levi S., Verardi R., Zanella I., Derosas M., Ingrassia R., Corrado M., Arosio P. RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood 2007, 109:3552-3559.
21. Boultwood J., Pellagatti A., Nikpour M., Pushkaran B., Fidler C., Cattan H., Littlewood T.J., Malcovati L., Della Porta M.G., Jadersten M., Killick S., Giagounidis A., Bowen D., Hellstrom-Lindberg E., Cazzola M., Wainscoat J.S. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PloS ONE 2008, 3:e1970.
22. Steensma D.P., Hecksel K.A., Porcher J.C., Lasho T.L. Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts). Leuk. Res. 2007, 31:623-628.
23. M. Nikpour, A. Pellagatti, A. Liu, M. Karimi, L. Malcovati, V. Gogvadze, A. Forsblom, J.S. Wainscoat, M. Cazzola, B. Zhivotovsky, A. Grandien, J. Boultwood, E. Hellstrom-Lindberg, Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. Br. J. Haematology (in press).
24. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
25. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D.J., Clark J.J., Lee S.J., Golub T.R., Wadleigh M., Gilliland D.G., Levine R.L. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3:e270.
26. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N., Warren A.J., Gilliland D.G., Lodish H.F., Green A.R. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007, 356:459-468.
27. Szpurka H., Tiu R., Murugesan G., Aboudola S., Hsi E.D., Theil K.S., Sekeres M.A., Maciejewski J.P. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006, 108:2173-2181.
28. E. Hellstrom-Lindberg, Significance of JAK2 and TET2 mutations in myelodysplastic syndromes. Blood Rev. 115 (2010) 1779-1784.
29. Raya J.M., Arenillas L., Domingo A., Bellosillo B., Gutierrez G., Luno E., Pinan M.A., Barbon M., Perez-Sirvent M.L., Muruzabal M.J., Yanez L., Garcia L., Lemes A., Navarro J.T., Elosegi A., Cortes M.A., Villegas A., Duran M.A., Ardanaz M., Florensa L. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status. Int. J. Hematol. 2008, 88:387-395.
30. Ingram W., Lea N.C., Cervera J., Germing U., Fenaux P., Cassinat B., Kiladjian J.J., Varkonyi J., Antunovic P., Westwood N.B., Arno M.J., Mohamedali A., Gaken J., Kontou T., Czepulkowski B.H., Twine N.A., Tamaska J., Csomer J., Benedek S., Gattermann N., Zipperer E., Giagounidis A., Garcia-Casado Z., Sanz G., Mufti G.J. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006, 20:1319-1321.
31. Malcovati L., Della Porta M.G., Pietra D., Boveri E., Pellagatti A., Galli A., Travaglino E., Brisci A., Rumi E., Passamonti F., Invernizzi R., Cremonesi L., Boultwood J., Wainscoat J.S., Hellstrom-Lindberg E., Cazzola M. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009, 114:3538-3545.
32. Schmitt-Graeff A.H., Teo S.S., Olschewski M., Schaub F., Haxelmans S., Kirn A., Reinecke P., Germing U., Skoda R.C. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008, 93:34-40.
33. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., Malinge S., Yao J., Kilpivaara O., Bhat R., Huberman K., Thomas S., Dolgalev I., Heguy A., Paietta E., Le Beau M.M., Beran M., Tallman M.S., Ebert B.L., Kantarjian H.M., Stone R.M., Gilliland D.G., Crispino J.D., Levine R.L. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
34. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Masse A., Kosmider O., Le Couedic J.P., Robert F., Alberdi A., Lecluse Y., Plo I., Dreyfus F.J., Marzac C., Casadevall N., Lacombe C., Romana S.P., Dessen P., Soulier J., Viguie F., Fontenay M., Vainchenker W., Bernard O.A. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 360:2289-2301.
35. Jankowska A.M., Szpurka H., Tiu R.V., Makishima H., Afable M., Huh J., O'Keefe C.L., Ganetzky R., McDevitt M.A., Maciejewski J.P. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113:6403-6410.
36. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., Stevens-Linders E., van Hoogen P., van Kessel A.G., Raymakers R.A., Kamping E.J., Verhoef G.E., Verburgh E., Hagemeijer A., Vandenberghe P., de Witte T., van der Reijden B.A., Jansen J.H. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41:838-842.
37. Mohamedali A.M., Smith A.E., Gaken J., Lea N.C., Mian S.A., Westwood N.B., Strupp C., Gattermann N., Germing U., Mufti G.J. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J. Clin. Oncol. 2009, 27:4002-4006.
38. Kosmider O., Gelsi-Boyer V., Ciudad M., Racoeur C., Jooste V., Vey N., Quesnel B., Fenaux P., Bastie J.N., Beyne-Rauzy O., Stamatoulas A., Dreyfus F., Ifrah N., de Botton S., Vainchenker W., Bernard O.A., Birnbaum D., Fontenay M., Solary E. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94:1676-1681.
39. Kosmider O., Gelsi-Boyer V., Cheok M., Grabar S., Della-Valle V., Picard F., Viguie F., Quesnel B., Beyne-Rauzy O., Solary E., Vey N., Hunault-Berger M., Fenaux P., Mansat-De Mas V., Delabesse E., Guardiola P., Lacombe C., Vainchenker W., Preudhomme C., Dreyfus F., Bernard O.A., Birnbaum D., Fontenay M. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes. Blood 2009, 114:3285-3291.
40. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (New York, N.Y.) 2009, 324:930-935.
41. Dunbar A.J., Gondek L.P., O'Keefe C.L., Makishima H., Rataul M.S., Szpurka H., Sekeres M.A., Wang X.F., McDevitt M.A., Maciejewski J.P. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008, 68:10349-10357.
42. Makishima H., Cazzolli H., Szpurka H., Dunbar A., Tiu R., Huh J., Muramatsu H., O'Keefe C., Hsi E., Paquette R.L., Kojima S., List A.F., Sekeres M.A., McDevitt M.A., Maciejewski J.P. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 2009, 27:6109-6116.
43. Reindl C., Quentmeier H., Petropoulos K., Greif P.A., Benthaus T., Argiropoulos B., Mellert G., Vempati S., Duyster J., Buske C., Bohlander S.K., Humphries K.R., Hiddemann W., Spiekermann K. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin. Cancer Res. 2009, 15:2238-2247.
44. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., Carbuccia N., Lagarde A., Prebet T., Nezri M., Sainty D., Olschwang S., Xerri L., Chaffanet M., Mozziconacci M.J., Vey N., Birnbaum D. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 2009, 145:788-800.
45. J. Boultwood, J. Perry, A. Pellagatti, M. Fernandez-Mercado, C. Fernandez-Santamaria, M.J. Calasanz, M.J. Larrayoz, M. Garcia-Delgado, A. Giagounidis, L. Malcovati, M.G. della Porta, M. Jadersten, S. Killick, E. Hellstrom-Lindberg, M. Cazzola, J.S. Wainscoat, Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia [Feb 25, 2010 Electronic publication ahead of print]. PMID: 20182461.
46. Fisher C.L., Pineault N., Brookes C., Helgason C.D., Ohta H., Bodner C., Hess J.L., Humphries R.K., Brock H.W. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010, 115:38-46.